FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021309127> ?p ?o ?g. }

• W2021309127 endingPage "R1" @default.
• W2021309127 startingPage "R1" @default.
• W2021309127 abstract "With the easy availability of thyroid hormone assays, thyroid disorders are now recognised even in a subclinical state. However, patients are still seen with advanced manifestations of the disease, particularly in developing countries. This observational study analysed the predictors of outcome in patients with myxoedema coma and tested the validity of different modules to define morbidity and mortality in these patients. Twenty-three consecutive patients with myxoedema coma who presented from January 1999 to August 2006 were studied. The thyroid function test and random serum cortisol were measured in all patients at the time of admission. Patients were given oral or intravenous (IV) thyroxine with intention to treat with the latter according to availability. Various modules that predict outcome, including Glasgow Coma Scale (GCS), Acute Physiology and Chronic Health Evaluation II (APACHE II) score, and Sequential Organ Failure Assessment (SOFA) score, were analysed. SOFA score was repeated every 2 days until the time of discharge or demise. Twenty-three patients (20 women; 87%) of 59.5 ± 14.4 years of age (range, 30 to 89 years) were seen during the study period. Nine (39%) patients were diagnosed with hypothyroidism for the first time at the time of presentation of myxoedema coma, whereas 14 (70%) were diagnosed with hypothyroidism previously. However, the treatment defaulters presented early to the hospital and had more severe manifestations than de novo subjects. Nineteen (82%) had thyroprivic (primary) and 4 (17%) had trophoprivic (secondary) hypothyroidism. Fifteen (65%) patients presented in the winter and in 17 (74%) sepsis was the major accompanying comorbidity. Twelve (52%) had a history of diuretic use, thereby delaying the initial diagnosis. Patients who received oral L-thyroxine had no difference in outcome from those receiving IV thyroxine. Twelve (52%) subjects died and sepsis was the predominant cause of death. Various predictors of mortality included hypotension (p = 0.01) and bradycardia (p = 0.03) at presentation, need for mechanical ventilation (p = 0.00), hypothermia unresponsive to treatment (p = 0.01), sepsis (p = 0.01), intake of sedative drugs (p = 0.02), lower GCS (p = 0.03), high APACHE II score (p = 0.04), and high SOFA score (p = 0.00). However, SOFA score was more effective than other predictive models as baseline and day 3 SOFA scores of more than 6 were highly predictive of poor outcome. L-Thyroxine treatment defaulters had more severe manifestations compared with de novo subjects. Outcome was not influenced by either aetiology or route of administration of L-thyroxine, and SOFA score was the best outcome predictor model." @default.
• W2021309127 created "2016-06-24" @default.
• W2021309127 creator A5020261528 @default.
• W2021309127 creator A5050665871 @default.
• W2021309127 creator A5056163184 @default.
• W2021309127 creator A5058963363 @default.
• W2021309127 creator A5060183060 @default.
• W2021309127 creator A5087291567 @default.
• W2021309127 date "2008-01-01" @default.
• W2021309127 modified "2023-10-16" @default.
• W2021309127 title "Predictors of outcome in myxoedema coma: a study from a tertiary care centre" @default.
• W2021309127 cites W112796459 @default.
• W2021309127 cites W127432472 @default.
• W2021309127 cites W1898928487 @default.
• W2021309127 cites W1974873560 @default.
• W2021309127 cites W1987820130 @default.
• W2021309127 cites W2010191128 @default.
• W2021309127 cites W2035545604 @default.
• W2021309127 cites W2040014691 @default.
• W2021309127 cites W2055506652 @default.
• W2021309127 cites W2071637551 @default.
• W2021309127 cites W2079382308 @default.
• W2021309127 cites W2113333006 @default.
• W2021309127 cites W2126386774 @default.
• W2021309127 cites W2151578177 @default.
• W2021309127 cites W2160362597 @default.
• W2021309127 cites W2166878339 @default.
• W2021309127 cites W2329807239 @default.
• W2021309127 cites W2394722817 @default.
• W2021309127 cites W3192016955 @default.
• W2021309127 cites W4248029140 @default.
• W2021309127 doi "https://doi.org/10.1186/cc6211" @default.
• W2021309127 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2374608" @default.
• W2021309127 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18173846" @default.
• W2021309127 hasPublicationYear "2008" @default.
• W2021309127 type Work @default.
• W2021309127 sameAs 2021309127 @default.
• W2021309127 citedByCount "106" @default.
• W2021309127 countsByYear W20213091272012 @default.
• W2021309127 countsByYear W20213091272013 @default.
• W2021309127 countsByYear W20213091272014 @default.
• W2021309127 countsByYear W20213091272015 @default.
• W2021309127 countsByYear W20213091272016 @default.
• W2021309127 countsByYear W20213091272017 @default.
• W2021309127 countsByYear W20213091272018 @default.
• W2021309127 countsByYear W20213091272019 @default.
• W2021309127 countsByYear W20213091272020 @default.
• W2021309127 countsByYear W20213091272021 @default.
• W2021309127 countsByYear W20213091272022 @default.
• W2021309127 countsByYear W20213091272023 @default.
• W2021309127 crossrefType "journal-article" @default.
• W2021309127 hasAuthorship W2021309127A5020261528 @default.
• W2021309127 hasAuthorship W2021309127A5050665871 @default.
• W2021309127 hasAuthorship W2021309127A5056163184 @default.
• W2021309127 hasAuthorship W2021309127A5058963363 @default.
• W2021309127 hasAuthorship W2021309127A5060183060 @default.
• W2021309127 hasAuthorship W2021309127A5087291567 @default.
• W2021309127 hasBestOaLocation W20213091271 @default.
• W2021309127 hasConcept C100136789 @default.
• W2021309127 hasConcept C113280763 @default.
• W2021309127 hasConcept C120665830 @default.
• W2021309127 hasConcept C121332964 @default.
• W2021309127 hasConcept C126322002 @default.
• W2021309127 hasConcept C141071460 @default.
• W2021309127 hasConcept C17624336 @default.
• W2021309127 hasConcept C187212893 @default.
• W2021309127 hasConcept C23131810 @default.
• W2021309127 hasConcept C2777465075 @default.
• W2021309127 hasConcept C2778384902 @default.
• W2021309127 hasConcept C2778840127 @default.
• W2021309127 hasConcept C2779159551 @default.
• W2021309127 hasConcept C2993291352 @default.
• W2021309127 hasConcept C526584372 @default.
• W2021309127 hasConcept C71924100 @default.
• W2021309127 hasConceptScore W2021309127C100136789 @default.
• W2021309127 hasConceptScore W2021309127C113280763 @default.
• W2021309127 hasConceptScore W2021309127C120665830 @default.
• W2021309127 hasConceptScore W2021309127C121332964 @default.
• W2021309127 hasConceptScore W2021309127C126322002 @default.
• W2021309127 hasConceptScore W2021309127C141071460 @default.
• W2021309127 hasConceptScore W2021309127C17624336 @default.
• W2021309127 hasConceptScore W2021309127C187212893 @default.
• W2021309127 hasConceptScore W2021309127C23131810 @default.
• W2021309127 hasConceptScore W2021309127C2777465075 @default.
• W2021309127 hasConceptScore W2021309127C2778384902 @default.
• W2021309127 hasConceptScore W2021309127C2778840127 @default.
• W2021309127 hasConceptScore W2021309127C2779159551 @default.
• W2021309127 hasConceptScore W2021309127C2993291352 @default.
• W2021309127 hasConceptScore W2021309127C526584372 @default.
• W2021309127 hasConceptScore W2021309127C71924100 @default.
• W2021309127 hasIssue "1" @default.
• W2021309127 hasLocation W20213091271 @default.
• W2021309127 hasLocation W20213091272 @default.
• W2021309127 hasLocation W20213091273 @default.
• W2021309127 hasLocation W20213091274 @default.
• W2021309127 hasLocation W20213091275 @default.
• W2021309127 hasOpenAccess W2021309127 @default.
• W2021309127 hasPrimaryLocation W20213091271 @default.

• next